Clinical trials: Adjuvant Drug Therapy
Breast Cancer
Study of Blood Samples in Patients With Breast Cancer
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to chemotherapy.
- Trial name
- NCT00959556
- Testing
- laboratory biomarker analysis
- Where
- France
- Sponsor
- Centre Oscar Lambret
Tumor
XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
The main objective of this clinical study is to evaluate the safety of XS005 injection; to determine the maximum tolerated dose . Furthermore, initial efficacy will be examined.
- Trial name
- NCT06147505
- Testing
- XS005 Injection
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Dushu Lake Hospital Affiliated to Soochow University
Peripheral Neuropathy Due to Chemotherapy
Acupuncture for Peripheral Neuropathy Induced by Paclitaxel in Early Stage Breast Cancer
The present study aims to evaluate the effectiveness of acupuncture in the treatment of chemotherapy drug paclitaxel induced peripheral neuropathy in patients with early stage breast cancer
- Trial name
- NCT04461977
- Testing
- True acupuncture
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Breast Cancer
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Investigators propose to study the efficacy of Bevacizumab plus systemic chemotherapy prior to surgery in order to make a locally advanced tumor operable.
- Trial name
- NCT01985841
- Testing
- Bevacizumb, 5-Fluorouracil, Epirubicin
- Where
- 6 sites in Greece
- Volunteers
- 34 people
- Sponsor
- Hellenic Oncology Research Group
Immunotherapy, Adjuvant Therapy
Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations
This is a two-group, parallel, randomized, standard-control phase II study comparing the safety and efficacy of immunotherapy versus standard chemotherapy in patients undergoing T4NX/TXN+ colon cancer surgery with MSI-H or POLE/…
- Conditions
- Immunotherapy, Adjuvant Therapy, Colon Cancer, MSI-H
- Trial name
- NCT04969029
- Testing
- Tirelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Nasopharyngeal Carcinoma
Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma
To see the effect if a combination of concurrent chemoradiotherapy followed by different adjuvant chemotherapy in treating patients with N2-3 nasopharyngeal carcinoma(NPC).
- Trial name
- NCT03321539
- Testing
- CCRT+GP, CCRT+PF
- Where
- 4 sites in China
- Volunteers
- 216 people
- Sponsor
- Sun Yat-sen University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Trial name
- NCT06876714
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography
- Where
- 702 sites in United States, Puerto Rico
- Volunteers
- 1,524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Endometrial Carcinoma
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma
Endometrial cancer, the most common gynecologic cancer worldwide, is steadily increasing in developed countries.The early-stage forms of endometrial cancer are usually highly curable by surgical treatment alone, whereas advanced…
- Trial name
- NCT06102252
- Testing
- Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sohag University
Chronic Myeloid Leukemia
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy
This is an extension of our ongoing clinical trial using ex vivo expanded autologous Cytokine-induced killer (CIK) cells as an adoptive cellular immunotherapy for haematological malignancies.
- Trial name
- NCT00815321
- Testing
- Autologous CIK cell infusion
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- Singapore General Hospital
Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of hepatic arterial infusion of liposomal irinotecan combined with systemic oxaliplatin and capecitabine as…
- Conditions
- Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer, Liver Metastasis
- Trial name
- NCT07570914
- Testing
- Liposomal Irinotecan, Oxaliplatin, Capecitabine
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Neutropenia
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
RATIONALE: Colony-stimulating factors, such as filgrastim or pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of…
- Trial name
- NCT00030758
- Testing
- filgrastim, pegfilgrastim
- Where
- 32 sites in United Kingdom
- Volunteers
- 816 people
- Sponsor
- Anglo Celtic Cooperative Oncology Group
Prostate Cancer Patients, Breast Cancer Patients
Cancer Survivors Program
The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating…
- Trial name
- SURV-QoL (NCT07253987)
- Testing
- active screening of adverse effects of anticancer therapy based on specific questionnaire + quality of life screening
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- Masaryk Memorial Cancer Institute
Gastrointestinal Tumors, Immunonutrition
Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors
Evaluate the effects of Suyusu (immunonutrition) in postoperative adjuvant chemotherapy for gastrointestinal cancer patients. The main endpoint of the study was the incidence of chemotherapy related adverse reactions (including…
- Conditions
- Gastrointestinal Tumors, Immunonutrition, Postoperative Adjuvant Chemotherapy
- Trial name
- NCT06085365
- Testing
- Immunonutrition （Su yusu), fluorouracil based chemotherapy regimens
- Where
- China
- Volunteers
- 324 people
- Sponsor
- China Medical University, China
Lung Metastases, Tumor Necrosis
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors.
- Trial name
- NCT03932071
- Testing
- Zoledronic Acid
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colon Cancer Stage
Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer
The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer
- Trial name
- NCT03645187
- Testing
- FOLFERI, Folferi and celecoxib
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sherief Abd-Elsalam
Colorectal Cancer
Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime
Oxaliplatin is a cytotoxic platinum compound and is one of the chemotherapeutic agent used in advanced colorectal cancer. It is used combined with Fluorouracil (5 FU) and Leucovorin.
- Trial name
- PENCOLA (NCT03542136)
- Testing
- VibrosSense Meter®
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Lund University Hospital
Sarcoma
Pazopanib Maintenance Phase II
This trial compares pazopanib to placebo as maintenance treatment over 2 years in patients with retroperitoneal and visceral high-risk soft tissue sarcomas after multimodal treatment including prior neo- and/or adjuvant…
- Trial name
- NCT02207309
- Testing
- Pazopanib
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Breast Cancer
Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Recent clinical studies showed that triple-negative breast cancer patients (ER-/PR-/HER2-) may benefit more from Capecitabine chemotherapy.
- Trial name
- NCT01642771
- Testing
- 5-Fu/epirubicin/CTX following Docetaxel, Docetaxel/capecitabine followed by XEC
- Where
- 37 sites in China
- Volunteers
- 636 people
- Sponsor
- China Breast Cancer Clinical Study Group
Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC
ML Decision Model for G-NEC Adjuvant Therapy
Gastric neuroendocrine carcinoma (G-NEC) is a rare and aggressive tumor originating from neuroendocrine cells in the stomach lining. It is characterized by a high propensity for recurrence and a generally poor prognosis.
- Conditions
- Gastric Neuroendocrine Carcinoma (G-NEC), Postoperative Adjuvant Therapy for G-NEC, Survival Outcomes, Machine Learning
- Trial name
- G-NEC (NCT06663852)
- Where
- China
- Volunteers
- 1,505 people
- Sponsor
- Chang-Ming Huang, Prof.
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ)…
- Trial name
- NCT04221555
- Testing
- Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.